March 29, 2011


Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective

 


Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective

Paris, France – March 29, 2011 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the registration statement relating to the Contingent Value Rights (CVRs) offered to Genzyme shareholders as part of sanofi-aventis’ agreement to acquire Genzyme has been declared effective by the U.S. Securities and Exchange Commission.